Xoma Technology Ltd.

Xoma (us) LLC

Novartis Ag

Musc Foundation for Research Development

Daniel H Bedinger

Amer M Mirza

Toshihiko Takeuchi

Shireen S Khan

Ajay J Narasimha

Kirk William Johnson

Marina Roell

Hassan Issafras

Agnes Choppin Holmes

Ou Li

Kiranjit Kaur Ahluwalia

Linda Masat

Isaac J Rondon

John Corbin

Mohammad Luqman

Mark Rubinstein

Jason Damiano

Raphael D Levy

Rachel A Hunt

Robyn Cotter

Hoa Giang

Lauren Schwimmer

Genevieve Nonet

Kristin Camfield Lind

Llewelyn Lao

Mark Leslie White

Robert Bauer

Paul Rubin

Ira Goldfine

The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Antibodies that bind interleukin-2 and uses thereof

The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.

Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatment

The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.

Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof

The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF&#x3b2;), including TGF&#x3b2;1, TGF&#x3b2;2 and TGF&#x3b2;3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF&#x3b2; expression.

Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3

Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (TGF)-&#x3b2;

The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia

The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.

Screening methods

TGF-beta-specific antibodies and methods of use thereof for treatment

Antibodies specific for TGF-&#x3b2;  and methods of treatment thereof

PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.

PRLR-specific antibody and uses thereof

Antibodies specific for TGF-beta and methods for treating thereof

The present disclosure relates to novel triple tag sequences that may comprise a 6&#xd7; histidine tag, a c-myc tag and a V5 tag. The present disclosure also provides polynucleotides, proteins, vectors and host cells that comprise the triple tag sequence of the present disclosure, including libraries of such polynucleotides, proteins, vectors and host cells. The novel triple tag sequences of the present disclosure may be used in phage display vectors and phage libraries and in methods for detection, screening, capture, purification, quantitation, and/or recovery of proteins of interest to which they are linked. Proteins of interest include antibodies such as single chain antibodies, single chain antibodies, and Fab fragments of antibodies or peptides such as non-antibody peptides.

Triple tag sequence and methods of use thereof

Triple tag sequences and methods of use thereof

Growing community of inventors

Berkeley, CA, United States of America

Daniel H Bedinger